“Efpeglenatide’s Beneficial Effect on Cardiovascular and Kidney Outcomes in High-Risk Type 2 Diabetes Patients, Regardless of Kidney-Related Risk Category”

https://pubmed.ncbi.nlm.nih.gov/38116691

The abstract reports that in high-risk people with type 2 diabetes, eGFR, UACR, and KDIGO category have distinct relationships with cardiovascular and kidney outcomes, and that efpeglenatide has a beneficial effect on these outcomes that is independent of kidney-related risk category.